Yellow Eyes: Drugs That Cause or Treat Jaundice

What Yellow Eyes Actually Mean

Yellow eyes occur when bilirubin, a byproduct of red blood cell breakdown, accumulates in the bloodstream and deposits in the sclera and skin. The medical term for yellowed sclerae is scleral icterus. Because the sclera has high elastin affinity for bilirubin, eye yellowing often appears before skin jaundice becomes obvious 1.

Bilirubin follows a specific metabolic pathway. Old red blood cells are dismantled in the spleen, releasing unconjugated (indirect) bilirubin. The liver then conjugates it with glucuronic acid, making it water-soluble so it can be excreted into bile. Any disruption along this chain, whether from excess red cell destruction (hemolysis), liver cell damage (hepatocellular injury), or blocked bile drainage (cholestasis), raises serum bilirubin and produces yellow eyes 2.

Normal total bilirubin ranges from 0.1 to 1.2 mg/dL. Clinical jaundice becomes detectable at roughly 2.5 to 3.0 mg/dL. Scleral icterus is often the earliest visible sign, detectable at bilirubin levels as low as 2.0 mg/dL in patients with lighter eye pigmentation 2. A level above 10 mg/dL in adults almost always indicates significant hepatobiliary or hemolytic disease and requires urgent workup.

Drug-Induced Liver Injury: The Most Common Medication-Related Cause

Drug-induced liver injury (DILI) is the single most important pharmacologic cause of yellow eyes. A prospective study from the Drug-Induced Liver Injury Network (DILIN) found that jaundice was present in approximately 70% of enrolled DILI cases, and among those with jaundice, roughly 10% progressed to acute liver failure 3. DILI accounts for about 10% of all acute hepatitis cases in Western countries and is the leading cause of acute liver failure in the United States 4.

DILI can be intrinsic (dose-dependent and predictable, like acetaminophen toxicity) or idiosyncratic (unpredictable, occurring at therapeutic doses in susceptible individuals). Idiosyncratic DILI may take days, weeks, or even months to appear after starting a medication. The latency period makes it easy to miss the connection between a new prescription and the onset of yellow eyes 3.

Hy's Law, described by the late hepatologist Hyman Zimmerman, states that a drug causing hepatocellular injury with jaundice (ALT >3x upper limit of normal plus bilirubin >2x upper limit of normal, without biliary obstruction) carries a case-fatality rate of 10% to 50% 4. The FDA now uses Hy's Law as a key signal during drug safety reviews. That statistic alone explains why yellow eyes in a patient on any hepatotoxic medication should prompt immediate evaluation.

Specific Drugs That Cause Yellow Eyes

The list of medications capable of producing jaundice is long. Below are the most clinically significant categories, organized by mechanism.

Hepatocellular Injury Pattern

Acetaminophen (Tylenol) is the prototypical dose-dependent hepatotoxin. Doses exceeding 4 grams per day in healthy adults, or lower thresholds in patients who drink alcohol regularly, can cause massive hepatocellular necrosis. An analysis from the Acute Liver Failure Study Group found acetaminophen responsible for 46% of all acute liver failure cases in the United States 5.

Isoniazid, used for tuberculosis prophylaxis and treatment, causes clinically significant hepatitis in about 1% of patients, with jaundice and fatal outcomes documented in case series 6. Risk increases with age over 35, daily alcohol use, and concurrent rifampin therapy. Monthly liver function monitoring is standard practice during isoniazid treatment.

Other notable hepatocellular offenders include methotrexate (used in rheumatoid arthritis and psoriasis), certain antiretrovirals like nevirapine, and the anti-epileptic valproic acid 4.

Cholestatic and Mixed Patterns

Amoxicillin-clavulanate (Augmentin) is the single most commonly reported cause of idiosyncratic DILI in most Western registries 3. It typically produces a cholestatic pattern with jaundice appearing 1 to 6 weeks after the antibiotic course, sometimes even after the course has ended. Most patients recover fully, but resolution may take several months.

Anabolic steroids, including testosterone derivatives used illicitly for bodybuilding, cause bland cholestasis by directly inhibiting bile salt transport proteins. The jaundice can be striking, with bilirubin levels exceeding 20 mg/dL, though liver synthetic function often remains intact 4.

Oral contraceptives and estrogen-containing hormone therapy can cause cholestatic jaundice in genetically predisposed individuals, particularly those with a history of intrahepatic cholestasis of pregnancy 7.

Statins (atorvastatin, rosuvastatin, simvastatin) cause transaminase elevations in 1% to 3% of users, but clinically apparent jaundice is rare. The American College of Cardiology/American Heart Association guidelines no longer recommend routine liver function monitoring for statin therapy, reflecting the low absolute risk of serious hepatotoxicity 8.

Hemolytic Drugs

Some medications cause yellow eyes not through liver damage but by destroying red blood cells. Dapsone, primaquine, and rasburicase can trigger hemolytic anemia, especially in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The resulting unconjugated hyperbilirubinemia produces scleral icterus with a normal or near-normal liver enzyme profile. The NIH LiverTox database catalogues over 1,000 drugs associated with liver injury and is a free resource maintained by the National Library of Medicine 9.

Drugs Used to Treat the Causes of Yellow Eyes

Treatment of yellow eyes targets the underlying etiology. No single drug "treats jaundice" as a standalone symptom. The bilirubin drops when the cause is corrected.

N-Acetylcysteine for Acetaminophen Overdose

N-acetylcysteine (NAC) is the specific antidote for acetaminophen-induced liver failure. When administered within 8 hours of overdose, NAC reduces mortality from acetaminophen hepatotoxicity to below 1%. A multicenter trial also found that intravenous NAC improved transplant-free survival in early-stage non-acetaminophen acute liver failure, from 30% in the placebo group to 52% in the NAC group 10. NAC works by replenishing hepatic glutathione stores and scavenging the toxic metabolite NAPQI.

Ursodeoxycholic Acid for Cholestatic Conditions

Ursodeoxycholic acid (UDCA, brand name Actigall) is the standard medical therapy for primary biliary cholangitis (PBC), a chronic autoimmune condition that destroys intrahepatic bile ducts and produces persistent jaundice. A meta-analysis in the Cochrane Database found that UDCA at 13 to 15 mg/kg/day improved liver biochemistry and slowed histological progression, though its effect on mortality remains debated 11.

For patients with PBC who have an inadequate response to UDCA, obeticholic acid (Ocaliva) gained FDA approval in 2016 as add-on therapy based on the POISE trial, which showed significant reductions in alkaline phosphatase 12.

Antivirals for Hepatitis-Related Jaundice

Viral hepatitis is a major global cause of jaundice. Direct-acting antiviral (DAA) regimens like sofosbuvir-velpatasvir (Epclusa) and glecaprevir-pibrentasvir (Mavyret) now cure hepatitis C in over 95% of patients across all genotypes, according to AASLD-IDSA guidelines 13. For hepatitis B, tenofovir and entecavir suppress viral replication and can reverse jaundice in patients with chronic HBV flares 14.

Corticosteroids for Autoimmune Hepatitis

Autoimmune hepatitis presenting with jaundice responds to prednisone, typically initiated at 40 to 60 mg daily and tapered over weeks. The American Association for the Study of Liver Diseases (AASLD) practice guidelines recommend combination therapy with azathioprine as a steroid-sparing agent to maintain remission 15. Biochemical remission, including normalization of bilirubin, occurs in approximately 80% of patients within 2 years of initiating therapy.

Chelation and Specific Therapies

Wilson disease, a genetic copper storage disorder, causes jaundice through hepatocellular damage. D-penicillamine and trientine chelate excess copper, while zinc acetate blocks intestinal copper absorption. Early treatment prevents progression to cirrhosis 16.

How Yellow Eyes Are Diagnosed

The diagnostic workup for scleral icterus is systematic. It starts with confirming true jaundice, then localizing where in the bilirubin pathway the problem lies.

A basic metabolic panel and hepatic function panel are drawn first. Total and direct bilirubin fractionation separates unconjugated from conjugated hyperbilirubinemia 2. Predominantly unconjugated (indirect) elevation points to hemolysis or Gilbert syndrome. Predominantly conjugated (direct) elevation points to hepatocellular damage or biliary obstruction.

ALT and AST levels help distinguish hepatocellular injury (markedly elevated transaminases) from cholestatic disease (elevated alkaline phosphatase and GGT with modestly raised transaminases). The R-ratio, calculated as (ALT/upper limit of normal) divided by (alkaline phosphatase/upper limit of normal), classifies DILI as hepatocellular (R >5), cholestatic (R <2), or mixed (R between 2 and 5) 3.

Right upper quadrant ultrasound is the first-line imaging study. It identifies gallstones, bile duct dilation, liver parenchymal abnormality, and masses. Magnetic resonance cholangiopancreatography (MRCP) provides detailed biliary anatomy when obstruction is suspected but not confirmed on ultrasound 17.

A thorough medication history is non-negotiable. The clinician should review every prescription drug, over-the-counter product, herbal supplement, and recreational substance. Herbal and dietary supplements now account for approximately 20% of DILI cases in the DILIN registry 3. Green tea extract, black cohosh, and multi-ingredient bodybuilding supplements are among the most frequently implicated.

When Yellow Eyes Require Emergency Care

Not all jaundice is equally dangerous. Gilbert syndrome, a benign genetic variant present in roughly 5% to 10% of the population, produces mild unconjugated hyperbilirubinemia that may cause faint scleral icterus during fasting, illness, or exertion. No treatment is needed 2.

The following scenarios demand urgent evaluation:

New scleral icterus plus dark urine and pale stools suggests biliary obstruction and may indicate a pancreatic or bile duct tumor requiring same-day imaging. Jaundice with fever, right upper quadrant pain, and rigors (Charcot triad) signals ascending cholangitis, a biliary infection that can progress to sepsis within hours 17.

Yellow eyes in a patient taking acetaminophen at doses above the recommended maximum, or in combination with alcohol, warrants immediate emergency department evaluation for N-acetylcysteine administration. Time to treatment directly determines survival.

"Any patient who develops jaundice while on a medication that is known to cause liver injury should have the drug discontinued immediately," per AASLD guidance on drug-induced liver injury 4. This applies even when the drug seems to be working well for the condition it was prescribed for.

Jaundice with mental status changes (confusion, somnolence, asterixis) indicates hepatic encephalopathy, a sign of acute liver failure. Coagulopathy (INR >1.5) plus encephalopathy plus jaundice defines acute liver failure and requires immediate transfer to a transplant center 5.

Preventing Drug-Induced Jaundice

Prevention starts with awareness. Patients beginning any medication listed as hepatotoxic should have baseline liver function tests drawn before the first dose 4. For high-risk drugs like isoniazid, methotrexate, and certain antiretrovirals, scheduled monitoring at defined intervals catches transaminase elevations before jaundice develops.

Acetaminophen toxicity is almost entirely preventable. Staying below 2 grams per day in patients who drink alcohol, and below 3 grams per day in all others, virtually eliminates the risk. Patients should be counseled that acetaminophen is an ingredient in hundreds of combination products, including cold remedies, sleep aids, and opioid-containing prescriptions 5.

For patients with known G6PD deficiency, avoiding oxidative drugs (dapsone, primaquine, nitrofurantoin, certain sulfonamides) prevents hemolytic episodes and the resulting unconjugated jaundice. The WHO recommends G6PD testing before prescribing primaquine for malaria treatment in endemic areas 18.

Patients with pre-existing liver disease face amplified risk from hepatotoxic drugs. Methotrexate, for example, carries a significantly higher risk of fibrosis in patients who already have fatty liver disease or hepatitis B/C coinfection 6. In these patients, the prescribing clinician should weigh alternatives and monitor more frequently. Any patient who notices yellowing of the eyes while taking a prescription medication should contact their healthcare provider the same day rather than waiting for the next scheduled appointment.